Subheading

Birgit Girshick began her career at the company in 1989 as an administrative assistant in Germany and has since risen to become CEO of Charles River Laboratories. Her promotion is a success story of internal talent development and emphasizes leadership continuity in the rapidly evolving Contract Research Organization (CRO) market. CROs are organizations that pharmaceutical and biotechnology companies outsource research and development to, seeking both efficiency and innovation.

Subheading

The CRO industry is currently undergoing a transformation towards data-driven platforms and digital solutions, with customer demands expanding towards more customized services. This shift requires a re-evaluation of existing operational approaches, and experienced internal leadership is crucial to guide strategic direction. CEO Girshick has stated her intention to balance organizational culture and technology investment, drawing on her past field experience.

Subheading

With competitors like Labcorp and IQVIA expanding their service portfolios, Charles River is strengthening its differentiated preclinical platform and global network. This signals growth potential to investors and signifies a more integrated solution offering for clients. In particular, efficiency improvements are highlighted as a key value in the early stages of drug development.

Subheading

Looking ahead, CEO Girshick plans to explore mergers and acquisitions (M&A) opportunities and invest in AI-based laboratory automation to expand service offerings. This is a strategy to secure a competitive advantage in a CRO market that is expected to grow at an annual rate of 7%. Across the industry, there is simultaneous pressure for service enhancement and cost reduction.